Neuroblastoma
Childhood Tumour Surgery › Neuroblastoma
Medically reviewed by Dr. Koushik Herle, MCh, DNB (Paediatric Surgery), Consultant Pediatric Surgeon and Pediatric Urologist, on 3 November 2026
Your young child has a swollen tummy. Or a limp that will not go away. Or dark bruising around the eyes, without any history of a fall. The ultrasound or CT scan shows a mass near the kidney. The word your doctor uses is neuroblastoma.
Neuroblastoma is a tumour of developing nerve tissue. It most often starts in the adrenal gland, which sits just above the kidney. Because it grows from early nerve cells (the sympathetic nervous system), it can also arise along the spine, in the tummy, chest, neck or pelvis.
It is one of the most common solid tumours of early childhood and is usually found before a child turns 5. Here is the part many families do not expect: neuroblastoma behaves very differently from child to child. Some tumours in babies shrink and disappear on their own without treatment. Others need intensive, combined treatment. Finding out which kind of tumour your child has is the first and most important step.
Key points for parents
Symptoms depend on where the tumour is growing and whether it has spread:
Do not wait. Take your child to the nearest emergency hospital if a child with a known or suspected tumour develops weakness in the legs, severe back pain with difficulty walking, inability to pass urine or stool, or sudden difficulty breathing. These can mean the tumour is pressing on the spinal cord or the airway, which is a medical emergency.
An ultrasound is usually the first test. A CT or MRI scan then shows the tumour and how it relates to the major blood vessels and the spine.
Neuroblastoma cells often release specific chemicals. A urine test for catecholamines (VMA and HVA) helps confirm the diagnosis. An MIBG scan, a nuclear medicine scan that about 90% of neuroblastomas take up, and a bone marrow test look for spread of the disease.
If the scans and urine tests point to neuroblastoma, a biopsy is usually needed. It is not only to name the tumour. Its most important job is to measure the tumour’s biology, above all whether the MYCN gene has extra copies (amplification). Tumours with MYCN amplification behave more aggressively.
This biological profile decides how intensive treatment needs to be. Where possible, the biopsy is taken by keyhole surgery (laparoscopy or thoracoscopy) or under image guidance, such as a CT-guided core biopsy.
Treatment is not planned by stage alone. It is planned by risk group, worked out from the child’s age, the extent of the tumour (stage) and its biology, including MYCN status. Paediatric oncology teams use frameworks such as the Children’s Oncology Group (COG) and the International Neuroblastoma Risk Group (INRG).
A related tumour, ganglioneuroma, is benign and fully matured. It does not spread and is treated by surgical removal alone.
Surgery is one specific part of a larger, coordinated plan. Neuroblastoma often wraps around major blood vessels such as the aorta and vena cava, so the surgery has to serve the overall plan and not the other way round.
Every surgical decision is made together with the pediatric oncologist and the family.
In some babies, yes. Certain low-risk neuroblastomas, especially in infants under about 12 to 18 months, can mature into benign tissue or shrink and disappear without treatment. These children are watched closely with scans and tests, and treated only if the tumour grows or causes problems.
No. Some low-risk tumours are treated with surgery alone or with careful observation. The need for chemotherapy depends on the child’s risk group.
Neuroblastoma often entangles important blood vessels. Chemotherapy can shrink the tumour and pull it away from these vessels. Operating after that can make the surgery safer and allow a more complete removal.
A pediatric oncologist and a pediatric surgeon, working together. Risk grouping and children’s tumour protocols are complex, so treatment should be planned by a dedicated multidisciplinary pediatric oncology team, with a pediatric oncology centre supporting high-risk treatment.
Consult your pediatric surgeon early to understand your options. Understanding your child’s risk group is the first step to the right plan.
For more on navigating a childhood cancer diagnosis, you may also wish to read the parents’ guide to Wilms tumour (kidney cancer).
Appointments: +91 8217553785
This page is educational information and is not a substitute for individual medical advice. Drafted with AI assistance and medically reviewed by Dr. Koushik Herle.